Showing 291-300 of 1743 results for "".
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur
- National Institutes of Health Allege Research Misconduct by Prominent Neuroscientist and Investigator of α-Synuclein in PD and ADhttps://practicalneurology.com/news/nih-alleges-research-misconduct-by-prominent-neuroscientist-and-investigator-of-a-synuclein-in-pd-and-ad/2470601/Eliezer Masliah, MD, director of the National Institutes of Aging (NIA) neuroscience division, has been accused of research misconduct via the falsification, duplication, and manipulation of images, particularly western blot images. Much of Dr. Masliah’s work focuses on the role of &al
- New Drug Application Is Submitted for Vamorolone for Treating Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-drug-application-is-submitted-for-vamorolone-for-treating-duchenne-muscular-dystrophy/2470058/The submission of a new drug application (NDA) to the Food and Drug Administration (FDA) has been completed, seeking priority review for vamorolone (Santhera Pharmaceuticals, Prattein, Switzerland; and ReveraGen BioPharma, Rockville, MD) for the treatment of Duchenne muscular dystrophy (DMD).&nbs
- Phenogroups of Migraine Identified With Artificial Intelligence-Guided Topologic Mappinghttps://practicalneurology.com/news/phenogroups-of-migraine-identified-with-artificial-intelligence-guided-topologic-mapping/2469941/Migraine is increasingly as a as a heterogeneous disorder, with a wide variety of headache characteristics, associated symptoms, and treatment responses. In a study presented at the American Headache Society meeting in Denver, CO June 9-12, 2022, Chia-Chun Chiang, MD, senior assoc
- Quest for Alzheimer Disease Treatments Continueshttps://practicalneurology.com/news/quest-for-alzheimer-disease-treatments-continues/2469577/The quest for effective treatment of Alzheimer disease (AD) continues as phase 2B and 3 clinical trials meet major milestones. Enrollment is complete for a trial of once-daily low dose of the antiseizure medication levetiracetam (AGB101; AgeneBio, Baltimore, MD) for treatment of a
- FDA Approves Casimersen for Duchenne Muscular Dystrophy Amenable to Exon 45 Skippinghttps://practicalneurology.com/news/fda-approves-casimersen-for-duchenne-muscular-dystrophy-amenable-to-exon-45-skipping/2469512/The Food and Drug Administration (FDA) granted approval for casimersen (Amondys 45; Sarepta Therapeutics, Silver Spring, MD) for treatment of Duchenne muscular dystrophy (DMD) caused by a dystrophin mutation amenable to exon 45 skipping. Casinmersen is an antisense oligonucleotide that blocks exo
- FDA Gives Market Clearance for Muscle Stimulator to Reduce Snoring and Mild Obstructive Sleep Apneahttps://practicalneurology.com/news/fda-gives-market-clearance-for-muscle-stimulator-to-reduce-snoring-and-mild-obstructive-sleep-apnea/2469494/The Food and Drug Administration (FDA) authorized a prescription-only device (eXciteOSA; Signifier Medical Technologies, Silver Spring, MD) to reduce snoring and mild obstructive sleep apnea. The device is used when the individuals is awake to improve tongue muscle function. FDA a